Compare FF & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FF | RANI |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.5M | 134.6M |
| IPO Year | N/A | 2021 |
| Metric | FF | RANI |
|---|---|---|
| Price | $3.41 | $1.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 208.2K | ★ 2.7M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | ★ 7.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $137,409,000.00 | $1,200,000.00 |
| Revenue This Year | N/A | $414.59 |
| Revenue Next Year | N/A | $30.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.09 | $0.39 |
| 52 Week High | $5.78 | $3.87 |
| Indicator | FF | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 50.22 | 40.73 |
| Support Level | $3.15 | $1.52 |
| Resistance Level | $3.49 | $1.67 |
| Average True Range (ATR) | 0.11 | 0.13 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 77.92 | 3.04 |
FutureFuel Corp makes and sells diversified chemical products, bio-based fuel products, and specialty chemical products. The company is organized into two segments based on product type: biofuels and chemicals. The biofuel segment sells biodiesel and other petroleum products. Its fuels are made from a mix of diesel, vegetable oils, and grease feedstock. The chemicals segment sells products that are used in the production of agricultural chemicals, which include herbicides, coatings, and cleaning products, such as detergents.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.